Gayed, J.; Bangad, V.; Xu, X.; Mensa, F.; Cutler, M.; Türeci, Ö.; Şahin, U.; Modjarrad, K.; Swanson, K.A.; Anderson, A.S.;
et al. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Vaccines 2024, 12, 734.
https://doi.org/10.3390/vaccines12070734
AMA Style
Gayed J, Bangad V, Xu X, Mensa F, Cutler M, Türeci Ö, Şahin U, Modjarrad K, Swanson KA, Anderson AS,
et al. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Vaccines. 2024; 12(7):734.
https://doi.org/10.3390/vaccines12070734
Chicago/Turabian Style
Gayed, Juleen, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A. Swanson, Annaliesa S. Anderson,
and et al. 2024. "Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial" Vaccines 12, no. 7: 734.
https://doi.org/10.3390/vaccines12070734
APA Style
Gayed, J., Bangad, V., Xu, X., Mensa, F., Cutler, M., Türeci, Ö., Şahin, U., Modjarrad, K., Swanson, K. A., Anderson, A. S., Gurtman, A., & Kitchin, N., on behalf of the C4591054 Study Group.
(2024). Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Vaccines, 12(7), 734.
https://doi.org/10.3390/vaccines12070734
